{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2013"],"data_sharing_plan":["IPD Sharing (as of March 2018): Undecided"],"condition":["Metastatic Colorectal Cancer","Colorectal Cancer","Colorectal Neoplasms","Metastatic colorectal cancer","Metastases"],"disease":["Metastatic Colorectal Cancer","Colorectal Cancer","Colorectal Neoplasms","Metastases"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2149795"],"location":["Netherlands"],"study_start_month":["12"],"keyword":["Capecitabine","Hand-foot syndrome","S1","Teysuno","Fluoropyrimidine","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.","description":"The study is a two-arm randomised phase III trial. Patients will be randomised to receive capecitabine (arm A) or S-1 (arm B). Bevacizumab may be added according to the choice of the investigator. Patients will be followed 3-weekly at the outpatient clinic, toxicity will be assessed according to study protocol guidelines. Patients will be evaluated every 3 cycles for response. Upon disease progression patients will be treated according to the local investigators","dates":{"creation":"2013-12-15"},"accession":"2149795","cross_references":{"ClinicalTrials___gov":["NCT01918852"],"EU Clinical Trials Register":["2013-002147-28"]}}